Drug analysis: Vectibix

  • ID: 4462147
  • Drug Pipelines
  • 23 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents the activation of EGFR and halts the cascade of intracellular signals dependent on this receptor. Preclinical studies have shown that Vectibix results in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Vectibix: Colorectal cancer (CRC)

List of Figures
Figure 1: Vectibix for colorectal cancer - SWOT analysis
Figure 2: Drug assessment summary of Vectibix for colorectal cancer
Figure 3: Drug assessment summary of Vectibix for colorectal cancer
Figure 4: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables
Table 1: Vectibix drug profile
Table 2: Overview of major approvals for Vectibix in colorectal cancer
Table 3: Vectibix pivotal trial data in colorectal cancer
Table 4: Vectibix early-phase data in colorectal cancer
Table 5: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 6: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016-25
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll